8 research outputs found
VMKDO: Verifiable multi-keyword search over encrypted cloud data for dynamic data-owner
Date online: 15 August 2016</p
Genetic and Functional Dissection of HTRA1 and LOC387715 in Age-Related Macular Degeneration
A common haplotype on 10q26 influences the risk of age-related macular degeneration (AMD) and encompasses two genes, LOC387715 and HTRA1. Recent data have suggested that loss of LOC387715, mediated by an insertion/deletion (in/del) that destabilizes its message, is causally related with the disorder. Here we show that loss of LOC387715 is insufficient to explain AMD susceptibility, since a nonsense mutation (R38X) in this gene that leads to loss of its message resides in a protective haplotype. At the same time, the common disease haplotype tagged by the in/del and rs11200638 has an effect on the transcriptional upregulation of the adjacent gene, HTRA1. These data implicate increased HTRA1 expression in the pathogenesis of AMD and highlight the importance of exploring multiple functional consequences of alleles in haplotypes that confer susceptibility to complex traits
Expert consensus on the diagnosis and treatment of RET gene fusion nonâsmall cell lung cancer in China
Abstract The rearranged during transfection (RET) gene is one of the receptor tyrosine kinases and cellâsurface molecules responsible for transmitting signals that regulate cell growth and differentiation. In nonâsmall cell lung cancer (NSCLC), RET fusion is a rare driver gene alteration associated with a poor prognosis. Fortunately, two selective RET inhibitors (sRETi), namely pralsetinib and selpercatinib, have been approved for treating RET fusion NSCLC due to their remarkable efficacy and safety profiles. These inhibitors have shown the ability to overcome resistance to multikinase inhibitors (MKIs). Furthermore, ongoing clinical trials are investigating several secondâgeneration sRETis that are specifically designed to target solvent front mutations, which pose a challenge for firstâgeneration sRETis. The effective screening of patients is the first crucial step in the clinical application of RETâtargeted therapy. Currently, four methods are widely used for detecting gene rearrangements: nextâgeneration sequencing (NGS), reverse transcriptionâpolymerase chain reaction (RTâPCR), fluorescence in situ hybridization (FISH), and immunohistochemistry (IHC). Each of these methods has its advantages and limitations. To streamline the clinical workflow and improve diagnostic and treatment strategies for RET fusion NSCLC, our expert group has reached a consensus. Our objective is to maximize the clinical benefit for patients and promote standardized approaches to RET fusion screening and therapy